Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Chronic Toxicology Studies of Basal Insulin Peglispro in Rats and Dogs: A Novel, PEGylated Insulin Lispro Analog with a Prolonged Duration of Action.

Byrd RA, Blackbourne JL, Knadler MP, Schultze AE, Vahle JL.

Toxicol Pathol. 2017 Apr;45(3):402-415. doi: 10.1177/0192623317696283. Epub 2017 Jan 1.

PMID:
28421968
2.

Quantification of Basal Insulin Peglispro and Human Insulin in Adipose Tissue Interstitial Fluid by Open-Flow Microperfusion.

Tiffner K, Boulgaropoulos B, Höfferer C, Birngruber T, Porksen N, Linnebjerg H, Garhyan P, Lam ECQ, Knadler MP, Pieber TR, Sinner F.

Diabetes Technol Ther. 2017 May;19(5):305-314. doi: 10.1089/dia.2016.0384. Epub 2017 Mar 22.

PMID:
28328234
3.

In Vitro and Clinical Evaluations of the Drug-Drug Interaction Potential of a Metabotropic Glutamate 2/3 Receptor Agonist Prodrug with Intestinal Peptide Transporter 1.

Pak YA, Long AJ, Annes WF, Witcher JW, Knadler MP, Ayan-Oshodi MA, Mitchell MI, Leese P, Hillgren KM.

Drug Metab Dispos. 2017 Feb;45(2):137-144. doi: 10.1124/dmd.116.071118. Epub 2016 Nov 28.

4.

Novel hepato-preferential basal insulin peglispro (BIL) does not differentially affect insulin sensitivity compared with insulin glargine in patients with type 1 and type 2 diabetes.

Porksen N, Linnebjerg H, Garhyan P, Lam EC, Knadler MP, Jacober SJ, Hoevelmann U, Plum-Moerschel L, Watkins E, Gastaldelli A, Heise T.

Diabetes Obes Metab. 2017 Apr;19(4):482-488. doi: 10.1111/dom.12834. Epub 2017 Feb 7.

PMID:
27888561
5.

Addition of 20-kDa PEG to Insulin Lispro Alters Absorption and Decreases Clearance in Animals.

Knadler MP, Nguyen TH, Campanale K, De Veer MJ, Beals JM, Li S, Hansen R, Siesky A, Michael MD, Porter CJ.

Pharm Res. 2016 Dec;33(12):2920-2929. Epub 2016 Aug 15.

6.

Reduced peripheral activity leading to hepato-preferential action of basal insulin peglispro compared with insulin glargine in patients with type 1 diabetes.

Mudaliar S, Henry RR, Ciaraldi TP, Armstrong DA, Burke PM, Pettus JH, Garhyan P, Choi SL, Knadler MP, Lam EC, Prince MJ, Bose N, Porksen NK, Sinha VP, Linnebjerg H, Jacober SJ.

Diabetes Obes Metab. 2016 Oct;18 Suppl 2:17-24. doi: 10.1111/dom.12753.

PMID:
27723226
7.

Disposition of Basal Insulin Peglispro Compared with 20-kDa Polyethylene Glycol in Rats Following a Single Intravenous or Subcutaneous Dose.

Knadler MP, Ellis BB, Brown-Augsburger PL, Murphy AT, Martin JA, Wroblewski VJ.

Drug Metab Dispos. 2015 Oct;43(10):1477-83. doi: 10.1124/dmd.115.064337. Epub 2015 Jul 14.

PMID:
26175543
8.

Effect of pomaglumetad methionil on the QT interval in subjects with schizophrenia.

Zhang W, Mitchell MI, Knadler MP, Long A, Witcher J, Walling D, Annes W, Ayan-Oshodi M.

Int J Clin Pharmacol Ther. 2015 Jun;53(6):462-70. doi: 10.5414/CP202289.

PMID:
25881753
9.

Relative contributions of presystemic and systemic peptidases to oral exposure of a novel metabotropic glutamate 2/3 receptor agonist (LY404039) after oral administration of prodrug pomaglumetad methionil (LY2140023).

Annes WF, Long A, Witcher JW, Ayan-Oshodi MA, Knadler MP, Zhang W, Mitchell MI, Cornelissen K, Hall SD.

J Pharm Sci. 2015 Jan;104(1):207-14. doi: 10.1002/jps.24226. Epub 2014 Nov 7.

PMID:
25382826
10.

Basal insulin peglispro demonstrates preferential hepatic versus peripheral action relative to insulin glargine in healthy subjects.

Henry RR, Mudaliar S, Ciaraldi TP, Armstrong DA, Burke P, Pettus J, Garhyan P, Choi SL, Jacober SJ, Knadler MP, Lam EC, Prince MJ, Bose N, Porksen N, Sinha VP, Linnebjerg H.

Diabetes Care. 2014 Sep;37(9):2609-15. doi: 10.2337/dc14-0210. Epub 2014 Jun 19.

PMID:
24947791
11.

Effects of duloxetine on norepinephrine and serotonin transporter activity in healthy subjects.

Chappell JC, Eisenhofer G, Owens MJ, Haber H, Lachno DR, Dean RA, Knadler MP, Nemeroff CB, Mitchell MI, Detke MJ, Iyengar S, Pangallo B, Lobo ED.

J Clin Psychopharmacol. 2014 Feb;34(1):9-16. doi: 10.1097/JCP.0000000000000061.

PMID:
24346757
12.

Nonclinical assessment of carcinogenic risk and tumor growth enhancement potential of prasugrel, a platelet-inhibiting therapeutic agent.

Buckley LA, Sanbuissho A, Starling JJ, Knadler MP, Iversen PW, Jakubowski JA.

Int J Toxicol. 2012 Jul-Aug;31(4):317-25. doi: 10.1177/1091581812445073. Epub 2012 Jun 12.

PMID:
22692976
13.

Effect of pitavastatin vs. rosuvastatin on international normalized ratio in healthy volunteers on steady-state warfarin.

Yu CY, Campbell SE, Zhu B, Knadler MP, Small DS, Sponseller CA, Hunt TL, Morgan RE.

Curr Med Res Opin. 2012 Feb;28(2):187-94. doi: 10.1185/03007995.2011.648264. Epub 2012 Jan 9.

PMID:
22149769
14.

Duloxetine: clinical pharmacokinetics and drug interactions.

Knadler MP, Lobo E, Chappell J, Bergstrom R.

Clin Pharmacokinet. 2011 May;50(5):281-94. doi: 10.2165/11539240-000000000-00000. Review.

PMID:
21366359
15.

Overview of metabolite safety testing from an industry perspective.

Anderson S, Knadler MP, Luffer-Atlas D.

Bioanalysis. 2010 Jul;2(7):1249-61. doi: 10.4155/bio.10.67. Review.

PMID:
21083238
16.

Effects of varying degrees of renal impairment on the pharmacokinetics of duloxetine: analysis of a single-dose phase I study and pooled steady-state data from phase II/III trials.

Lobo ED, Heathman M, Kuan HY, Reddy S, O'Brien L, Gonzales C, Skinner M, Knadler MP.

Clin Pharmacokinet. 2010 May;49(5):311-21. doi: 10.2165/11319330-000000000-00000.

PMID:
20384393
17.

Effects of duloxetine on the pharmacodynamics and pharmacokinetics of warfarin at steady state in healthy subjects.

Chappell J, He J, Knadler MP, Mitchell M, Lee D, Lobo E.

J Clin Pharmacol. 2009 Dec;49(12):1456-66. doi: 10.1177/0091270009344335. Epub 2009 Sep 30.

PMID:
19793910
18.

Population pharmacokinetics of orally administered duloxetine in patients: implications for dosing recommendation.

Lobo ED, Quinlan T, O'Brien L, Knadler MP, Heathman M.

Clin Pharmacokinet. 2009;48(3):189-97. doi: 10.2165/00003088-200948030-00005. Erratum in: Clin Pharmacokinet. 2011 Oct 1;50(10):687-8.

PMID:
19385712
19.

Predicting circulating human metabolites: how good are we?

Anderson S, Luffer-Atlas D, Knadler MP.

Chem Res Toxicol. 2009 Feb;22(2):243-56. doi: 10.1021/tx8004086.

PMID:
19138063
20.

Hepatic effects of duloxetine-I: non-clinical and clinical trial data.

Wernicke J, Pangallo B, Wang F, Murray I, Henck JW, Knadler MP, D'Souza DN, Uetrecht JP.

Curr Drug Saf. 2008 May;3(2):132-42. Review. Erratum in: Curr Drug Saf. 2009 Jan;4(1):94.

PMID:
18690991
21.

In vitro and in vivo evaluations of cytochrome P450 1A2 interactions with duloxetine.

Lobo ED, Bergstrom RF, Reddy S, Quinlan T, Chappell J, Hong Q, Ring B, Knadler MP.

Clin Pharmacokinet. 2008;47(3):191-202.

PMID:
18307373
22.

Pharmacokinetics of duloxetine in breast milk and plasma of healthy postpartum women.

Lobo ED, Loghin C, Knadler MP, Quinlan T, Zhang L, Chappell J, Lucas R, Bergstrom RF.

Clin Pharmacokinet. 2008;47(2):103-9.

PMID:
18193916
23.

Pharmacokinetics and tolerability of duloxetine following oral administration to healthy Chinese subjects.

Tianmei S, Knadler MP, Lim MT, Yeo KP, Teng L, Liang S, Pan AX, Lobo ED.

Clin Pharmacokinet. 2007;46(9):767-75.

PMID:
17713974
24.

QT effects of duloxetine at supratherapeutic doses: a placebo and positive controlled study.

Zhang L, Chappell J, Gonzales CR, Small D, Knadler MP, Callaghan JT, Francis JL, Desaiah D, Leibowitz M, Ereshefsky L, Hoelscher D, Leese PT, Derby M.

J Cardiovasc Pharmacol. 2007 Mar;49(3):146-53.

PMID:
17414226
25.

Duloxetine pharmacokinetics are similar in Japanese and Caucasian subjects.

Chan C, Yeo KP, Pan AX, Lim M, Knadler MP, Small DS.

Br J Clin Pharmacol. 2007 Mar;63(3):310-4. Epub 2006 Sep 12.

26.

Development and validation of a liquid chromatography-tandem mass spectrometric method for the determination of the major metabolites of duloxetine in human plasma.

Satonin DK, McCulloch JD, Kuo F, Knadler MP.

J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Jun 1;852(1-2):582-9. Epub 2007 Feb 21.

PMID:
17350901
27.

The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression.

Bymaster FP, Lee TC, Knadler MP, Detke MJ, Iyengar S.

Curr Pharm Des. 2005;11(12):1475-93. Review.

PMID:
15892657
28.

Duloxetine pharmacokinetics in cirrhotics compared with healthy subjects.

Suri A, Reddy S, Gonzales C, Knadler MP, Branch RA, Skinner MH.

Int J Clin Pharmacol Ther. 2005 Feb;43(2):78-84.

PMID:
15726876
29.

Effect of duloxetine on tolterodine pharmacokinetics in healthy volunteers.

Hua TC, Pan A, Chan C, Poo YK, Skinner MH, Knadler MP, Gonzales CR, Wise SD.

Br J Clin Pharmacol. 2004 May;57(5):652-6.

30.

Effect of age on the pharmacokinetics of duloxetine in women.

Skinner MH, Kuan HY, Skerjanec A, Seger ME, Heathman M, O'Brien L, Reddy S, Knadler MP.

Br J Clin Pharmacol. 2004 Jan;57(1):54-61.

31.

Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects.

Lantz RJ, Gillespie TA, Rash TJ, Kuo F, Skinner M, Kuan HY, Knadler MP.

Drug Metab Dispos. 2003 Sep;31(9):1142-50.

PMID:
12920170
32.

Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers.

Skinner MH, Kuan HY, Pan A, Sathirakul K, Knadler MP, Gonzales CR, Yeo KP, Reddy S, Lim M, Ayan-Oshodi M, Wise SD.

Clin Pharmacol Ther. 2003 Mar;73(3):170-7.

PMID:
12621382
33.

Divergent effects of raloxifene HCI on the pharmacokinetics and pharmacodynamics of warfarin.

Miller JW, Skerjanec A, Knadler MP, Ghosh A, Allerheiligen SR.

Pharm Res. 2001 Jul;18(7):1024-8.

PMID:
11496940
34.

Raloxifene reduces atherosclerosis: studies of optimized raloxifene doses in ovariectomized, cholesterol-fed rabbits.

Bjarnason NH, Haarbo J, Byrjalsen I, Kauffman RF, Knadler MP, Christiansen C.

Clin Endocrinol (Oxf). 2000 Feb;52(2):225-33.

PMID:
10671951
35.
36.

Stereoselective disposition of flurbiprofen in uraemic patients.

Knadler MP, Brater DC, Hall SD.

Br J Clin Pharmacol. 1992 Apr;33(4):377-83.

37.

Stereoselective disposition of flurbiprofen in normal volunteers.

Knadler MP, Brater DC, Hall SD.

Br J Clin Pharmacol. 1992 Apr;33(4):369-75.

38.

Pulmonary inversion of 2-arylpropionic acids: influence of protein binding.

Hall SD, Hassanzadeh-Khayyat M, Knadler MP, Mayer PR.

Chirality. 1992;4(6):349-52.

PMID:
1449949
39.

Metabolism of the anticoagulant peptide, MDL 28,050, in rats.

Knadler MP, Ackermann BL, Coutant JE, Hurst GH.

Drug Metab Dispos. 1992 Jan-Feb;20(1):89-95.

PMID:
1347003
40.

Stereoselective hydrolysis of flurbiprofen conjugates.

Knadler MP, Hall SD.

Drug Metab Dispos. 1991 Jan-Feb;19(1):280-2. No abstract available.

PMID:
1673415
41.

Secretion of nizatidine into human breast milk after single and multiple doses.

Obermeyer BD, Bergstrom RF, Callaghan JT, Knadler MP, Golichowski A, Rubin A.

Clin Pharmacol Ther. 1990 Jun;47(6):724-30.

PMID:
1972674
42.

Stereoselective arylpropionyl-CoA thioester formation in vitro.

Knadler MP, Hall SD.

Chirality. 1990;2(2):67-73.

PMID:
2400639
43.
44.

Plasma protein binding of flurbiprofen: enantioselectivity and influence of pathophysiological status.

Knadler MP, Brater DC, Hall SD.

J Pharmacol Exp Ther. 1989 May;249(2):378-85.

PMID:
2724130
45.

Absorption studies of the H2-blocker nizatidine.

Knadler MP, Bergstrom RF, Callaghan JT, Obermeyer BD, Rubin A.

Clin Pharmacol Ther. 1987 Nov;42(5):514-20. Erratum in: Clin Pharmacol Ther 1991 Mar;49(3):255.

PMID:
2890459
46.

Nizatidine, and H2-receptor antagonist: disposition and safety in the elderly.

Callaghan JT, Rubin A, Knadler MP, Bergstrom RF.

J Clin Pharmacol. 1987 Aug;27(8):618-24.

PMID:
2888796
47.

A pharmacokinetic profile of nizatidine in man.

Callaghan JT, Bergstrom RF, Rubin A, Chernish S, Crabtree R, Knadler MP, Obermeyer B, Offen WW, Schneck DW, Aronoff G, et al.

Scand J Gastroenterol Suppl. 1987;136:9-17. Review. Erratum in: Scand J Gastroenterol Suppl 1991 Aug;26(8):preceding 801.

PMID:
2892261
48.

Nizatidine, an H2-blocker. Its metabolism and disposition in man.

Knadler MP, Bergstrom RF, Callaghan JT, Rubin A.

Drug Metab Dispos. 1986 Mar-Apr;14(2):175-82.

PMID:
2870891
49.

Stereoselective inversion of (R)-fenoprofen to (S)-fenoprofen in humans.

Rubin A, Knadler MP, Ho PP, Bechtol LD, Wolen RL.

J Pharm Sci. 1985 Jan;74(1):82-4.

PMID:
3920382

Supplemental Content

Loading ...
Support Center